Anmeldung zur Tagung
Registration
Grußwort
Invitation
Themen
Topics
Allgemeiner Ablauf
General overview
Wissenschaftliches Programm
Scientific program
Kurse
Courses
Symposien
Symposiums
Frühstück mit Spezialisten
Breakfast with specialists
Arzthelferinnen-Fortbildung
Rahmenprogramm
Social program
DOG Information
DOG Information
Allgemeine Informationen
General Information
Autorenindex
Index of Authors
Ausstellerliste
Exhibitors
Sponsoren
Sponsors
Teilnahmegebühren
Registration fees
Impressum
Cystoid macular edema associated with latanoprost therapy in a pseudophakic vitrectomized patient
Jäger M., Jonas J. B.
Augenklinik, Fakultät für klinische Medizin Mannheim, Ruprecht-Karls- Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim
Introduction: Latanoprost (0.005%) is a prostaglandin F2a analogue
and has become one of the most widely used medications for treatment of
primary open-angle glaucoma. We describe the occurrence of cystoid macular
edema in a pseudophakic vitrectomized patient following its use.
Case Report: A 58-years old patient had undergone routine uncomplicated
cataract surgery with posterior chamber lens implantation. Three months
later, he developed rhegmatogenous retinal detachment which was treated
by pars plana vitrectomy with silicone oil endotamponade. The latter was
removed 6 months later. Five months after oil removal, the patient presented
with secondary open-angle glaucoma which was treated with latanoprost
0.005% eye drops once daily. Two weeks after initiation of latanoprost
treatment, visual acuity dropped from 0.8 to 0.3 due to cystoid macular
edema confirmed by fluorescein angiography. After discontinuing latanoprost
therapy and with topical corticosteroid treatment, cystoid macular edema
slowly resolved, and within 6 months visual acuity improved to 0.6.
Conclusion: Despite its marked ocular hypotensive effect, latanoprost
should be carefully used in patients after uncomplicated cataract surgery,
if the vitreous body was removed by pars plana vitrectomy.